Bellicum Pharmaceuticals Inc.:
Molecular switch technology and co-stim domains enables pharmacologic control over cells for enhanced efficacy and safety. Lead (registrational EU) program: Ph2 for rivo-cel (alpha/beta addback T-cell therapy for post allogeneic HSTC in non-malignant and malignant diseases). Positive late interim analysis on rivo-cel exp at ASH 2018; full dataset (N=234) exp H1 19. BPX-601: GoCAR-T featuring iMC (inducible MyD88/CD40) activation switch targeting PSCA expressing solid tumors; BPX-701: TCR targeting PRAME.
US - West South Central
Phase l or ll
Immuno-Oncology, Oncology, Rare Disease
2130 West Holcombe Boulevard, Suite 800
Texas Life Science Plaza
Houston, TX 77030
Top 10 Holders of Bellicum Pharmaceuticals Inc
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by